A gastric bypass side effect with no approved treatment cleared phase 3 by a wide margin

Amylyx Pharmaceuticals announced topline results 18 August from LUCIDITY, a Phase 3 trial of avexitide in post-bariatric hypoglycemia — a condition with no FDA-approved treatment, affecting an estimated 8% of US bariatric surgery patients, or roughly 160,000 people [s1]. The trial met its primary endpoint with a 55% reduction in severe hypoglycemic events against placebo, at a p-value of 0.000003 [s1].

What post-bariatric hypoglycemia actually is

The condition develops after Roux-en-Y gastric bypass or sleeve gastrectomy surgery, causing recurrent, sudden drops in blood glucose — a paradoxical complication of a procedure performed to treat obesity and metabolic disease, not something patients are typically warned to expect as a lasting risk [s1]. Unlike the more familiar hypoglycemia risk in diabetes treatment, there is currently no drug approved specifically for this post-surgical condition, leaving patients and clinicians managing it through dietary strategies alone [s1].

The trial's design and what "55%" actually measures

LUCIDITY enrolled 78 participants across 21 US sites, randomizing them 3:2 to 90 mg of avexitide by daily injection or placebo, over a 16-week double-blind period followed by a 32-week open-label extension in which all participants could receive the drug [s1]. The primary endpoint combined Level 2 and Level 3 hypoglycemic events — the more clinically serious tiers of low blood sugar, as opposed to milder Level 1 dips — and the drug reduced that composite rate by 55% relative to placebo [s1]. A p-value of 0.000003 indicates the result is extremely unlikely to be a statistical fluke, though a p-value this small speaks to the statistical confidence in the direction and reliability of the effect, not to its exact clinical magnitude — that's a separate question about how meaningfully fewer severe episodes translates into a patient's actual quality of life, which this topline announcement doesn't quantify beyond the event-rate reduction itself.

The secondary results and safety profile

Amylyx reported that every secondary endpoint also reached statistical significance in the same direction: fewer Level 2 events measured by patient self-monitoring, fewer Level 2 events measured by continuous glucose monitoring, and fewer independently adjudicated Level 3 events [s1]. On safety, the company describes avexitide as generally well-tolerated, with the most common adverse events being diarrhea and injection-site redness or bruising, all mild to moderate, with no serious treatment-related adverse events and no observed change in body weight [s1].

Why this is topline data, not full peer-reviewed results

Everything reported here comes from the company's own announcement of its topline findings — a standard, common way trial sponsors disclose major results quickly, but it is not the same as a peer-reviewed publication with full statistical methodology, complete adverse-event tables, and independent expert scrutiny. Amylyx's Chief Medical Officer Camille Bedrosian framed the results as bringing the company "one step closer to potentially delivering the first approved treatment" for the condition [s1] — language that itself signals this is a step in a longer regulatory process, not a finished one.

What comes next, and on what timeline

Amylyx says it plans to submit a New Drug Application to the FDA by the end of 2026, targeting a possible commercial launch in 2027 if approved [s1]. The FDA has already granted avexitide Breakthrough Therapy Designation for post-bariatric hypoglycemia and Orphan Drug Designation for a related condition, hyperinsulinemic hypoglycemia [s1] — both of which can speed regulatory review, but neither of which guarantees eventual approval.

What to watch next

Whether the full peer-reviewed dataset, once published, confirms the topline numbers and adds the clinical-significance context this announcement doesn't provide, and whether the FDA's review of the eventual NDA submission raises questions the 16-week double-blind window didn't have time to answer — particularly around longer-term safety, given the trial's open-label extension only reaches 48 weeks total.